Published in Pharma Law Weekly, September 27th, 2005
The two proprietary compounds are NAP, from which Allon has derived its first and second products AL-108 and AL-208, and ADNF-9, from which the company has derived product candidates now undergoing preclinical studies. AL-108 is being evaluated in phase I human clinical trials as a treatment for Alzheimer disease. AL-208 is being evaluated in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly